In a separate study of 72 patients with T1DM and overweight or obesity, liraglutide (1.2 mg and 1.8 mg) over 12 weeks resulted in modest reductions in glucose levels, HbA1c, and significant weight loss (5 ± 1 kg), along with small reductions in total insulin dose (-10-12 IU). Here, INS is linked to obesity disorder.